Analyses of IL-6, IL-10, IL-17A, INF-γ and TNF-α Cytokines in Diseases of Mucopolysaccharidosis Type I and Mucopolysaccharidoses Type VI

B.J. Vieira¹, A.S. Blembeel¹, G.P. Dorneles², J. Cé³, A. Peres^{1, 2}, J.C. Coelho³ and A.S. Mello^1,

¹IPA Methodist University Center (Centro Universitário Metodista IPA). Porto Alegre, Brazil

²Federal University of Health Sciences of Porto Alegre (Universidade Federal de Ciências da Saúde de Porto Alegre). Porto Alegre, Brazil

³Federal University of Rio Grande do Sul (Universidade Federal do Rio Grande do Sul). Porto Alegre, Brazil

Cite this paper

B.J. Vieira, A.S. Blembeel, G.P. Dorneles, J. Cé, A. Peres, J.C. Coelho and A.S. Mello. Analyses of IL-6, IL-10, IL-17A, INF-γ and TNF-α Cytokines in Diseases of Mucopolysaccharidosis Type I and Mucopolysaccharidoses Type VI. American Journal of Biomedical Research. 2019; 7(1):3-8. doi: 10.12691/AJBR-7-1-2

Abstract

Background: Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases, which are caused by the deficiency of one of the enzymes essential for the catabolism of Glycosaminoglycans. Seven different types of MPS have already been identified, and some are classified into subtypes depending on which enzyme is deficient as correlated to clinical findings. This article aims to evaluate some cytokines in order to understand the immunological relationship in plasma samples of patients with MPS type I (MPS I) and in leukocyte samples of patients with MPS type VI (MPS VI) by comparing healthy individual controls. Methods: 28 subjects (MPS I = 7, healthy controls = 7 and MPS VI = 7; healthy controls = 7) as well as dosages of IL-6, IL-10, IL-17A and TNF-α which were determined by ELISA. Results: In both comparisons that were performed, TNF-α levels were different among MPS I and MPS VI individuals when compared to healthy controls, suggesting that this cytokine could be a potential inflammatory marker for disease monitoring. On the other hand, IL-17A showed a negative correlation with IL-6 only in individuals with MPS VI, confirming the variability of multi-systemic symptoms of this disease. Conclusions: The results presented in this article show a relationship between human genetics and immunology, trying to monitor different stages of life of patients with these diseases, in order to improve their quality of life. The analysis of the cytokine profile is very important in the evaluation of the relation between diseases and their systemic effects.

Keywords

Mucopolysaccharidoses, Lysosomal storage diseases, Inborn errors of metabolism

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Crocker J. The metabolic and molecular bases of inherited disease CD-ROM. Mol Pathol 1997; 50: 279.
[2]	Giugliani R, Federhen A, Rojas MVM, Vieira T, Artigalás O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol 2010; 33: 589-604.
[3]	Azevedo A, Schwartz I, Kalakun L, Brustolin S, Burin M, Beheregaray A, et al., Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI, Clin Genet 2004; 66: 208-213.
[4]	Dinarello CA, Mier JW. Interleukins, Annu Rev Med 1986; 37: 173-178.
[5]	Peake JM, Suzuki K, Hordern M, Wilson G, Nosaka K, Coombes JS. Plasma cytokine changes in relation to exercise intensity and muscle damage, Eur J Appl Physiol 2005; 95: 514-521.
[6]	Vilček J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics, Trends Pharmacol Sci 2004; 25: 201-209.
[7]	Elenkov IJ, Chrousos GP, Wilder RL. Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann N Y Acad Sci 2000; 917: 94-105.
[8]	Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect 2013; 2: e60.
[9]	Eliyahu E, Wolfson T, Ge Y, Jepsen KJ, Schuchman EH, Simonaro CM. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS One 2011; 6: e22447.
[10]	Frohbergh M, Ge Y, Meng F, Karabul N, Solyom A, Lai A, et al. Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI Rats and Comparison to Oral Treatment. PLoS One. 2014; 9: e100882.
[11]	Polgreen LE, Vehe RK, Rudser K, Kunin-Batson A, Utz JJ, Dickson P, et al. Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI. Mol Genet Metab 2016; 117: 427-430.
[12]	Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127: 117-126.
[13]	Oliveira CMB, Sakata RK, Issy AM, Gerola LR, Salomão R. Citocinas e Dor. Rev Bras Anestesiol 2011; 61: 255-265.
[14]	Hopwood JJ, Muller V, Smithson A, Baggett N. A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta 1979; 92: 257-265.
[15]	Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
[16]	Kresse H, von Figura K, Klein U, Glössl J, Paschke E, Pohlmann R. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol 1982; 83: 559-572.
[17]	Torres LC, Soares DCQ, Kulikowski LD, Franco JF, Kim CA. NK and B cell deficiency in a MPS type II family with novel mutation in the IDS gene. Clin Immunol 2014; 154: 100-104.
[18]	Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrino Metab 2005; 288: E155-E162, 2004.
[19]	Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75: 40-47.
[20]	Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the Toll-like receptor 4 pathway and use of TNF-  antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci 2010; 107: 222-227.
[21]	Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI, Pediatrics 2007; 120: 405-418.
[22]	Harmatz P. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (maroteaux-lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-Acetylga. Pediatrics 2005; 115: e681-e689.
[23]	Killedar S, Dirosario J, Divers E, Popovich PG, McCarty DM, Fu H. Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J Neuroinflammation 2010; 7: 39.
[24]	Souza OR, Matos JR, Oliveira RT, Blotta MH, Coelho SL. Serum levels of interleukin-6 (IL-6), interleukin-18 (IL-18) and c-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without st-segment elevation. Inflamm Markers Diabet Patients 2008; 90: 86-90.
[25]	Donida B, Marchetti DP, Biancini GB, Deon M, Manini PR, da Rosa HT, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta - Mol Basis Dis 2015; 1852: 1012-1019.
[26]	Inoue M, Arikawa T, Chen YH, Moriwaki Y, Price M, Brown M, et al. T cells down-regulate macrophage TNF production by IRAK1-mediated IL-10 expression and control innate hyperinflammation. Proc Natl Acad Sci USA 2014; 111: 5295-300.
[27]	Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012; 819467.
[28]	Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008; 43: 402-407.